Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older
< b > Conditions < /b > : Meningitis; Meningococcal Meningitis; Meningococcal Infections < br/ > < b > Interventions < /b > : Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine; Biological: Meningococcal Polysaccharide Vaccine, Groups A, C, Y, and W 135 Combined < br/ > < b > Sponsor < /b > : Sanofi Pasteur, a Sanofi Company < br/ > < b > Recruiting < /b > - verified July 2016 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 15, 2016 Category: Research Source Type: clinical trials
Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine
< b > Conditions < /b > : Meningitis; Meningococcal Meningitis; Meningococcal Infections < br/ > < b > Interventions < /b > : Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine; Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine; Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine; Biological: Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine < br/ > < b > Sponsor < /b > : Sanofi Pasteur, a Sanofi Co...
Source: ClinicalTrials.gov - July 15, 2016 Category: Research Source Type: clinical trials
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older
< b > Conditions < /b > : Meningitis; Meningococcal Meningitis; Meningococcal Infections < br/ > < b > Interventions < /b > : Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine; Biological: Meningococcal Polysaccharide Vaccine, Groups A, C, Y, and W 135 Combined < br/ > < b > Sponsor < /b > : Sanofi Pasteur, a Sanofi Company < br/ > < b > Recruiting < /b > - verified July 2016 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 15, 2016 Category: Research Source Type: clinical trials
Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine
< b > Conditions < /b > : Meningitis; Meningococcal Meningitis; Meningococcal Infections < br/ > < b > Interventions < /b > : Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine; Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine; Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine; Biological: Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine < br/ > < b > Sponsor < /b > : Sanofi Pasteur, a Sanofi Co...
Source: ClinicalTrials.gov - July 15, 2016 Category: Research Source Type: clinical trials
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older
< b > Conditions < /b > : Meningitis; Meningococcal Meningitis; Meningococcal Infections < br/ > < b > Interventions < /b > : Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine; Biological: Meningococcal Polysaccharide Vaccine, Groups A, C, Y, and W 135 Combined < br/ > < b > Sponsor < /b > : Sanofi Pasteur, a Sanofi Company < br/ > < b > Recruiting < /b > - verified July 2016 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 15, 2016 Category: Research Source Type: clinical trials
Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine
< b > Conditions < /b > : Meningitis; Meningococcal Meningitis; Meningococcal Infections < br/ > < b > Interventions < /b > : Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine; Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine; Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine; Biological: Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine < br/ > < b > Sponsor < /b > : Sanofi Pasteur, a Sanofi Co...
Source: ClinicalTrials.gov - July 15, 2016 Category: Research Source Type: clinical trials
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older
< b > Conditions < /b > : Meningitis; Meningococcal Meningitis; Meningococcal Infections < br/ > < b > Interventions < /b > : Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine; Biological: Meningococcal Polysaccharide Vaccine, Groups A, C, Y, and W 135 Combined < br/ > < b > Sponsor < /b > : Sanofi Pasteur, a Sanofi Company < br/ > < b > Recruiting < /b > - verified July 2016 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 15, 2016 Category: Research Source Type: clinical trials
Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine
< b > Conditions < /b > : Meningitis; Meningococcal Meningitis; Meningococcal Infections < br/ > < b > Interventions < /b > : Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine; Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine; Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine; Biological: Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine < br/ > < b > Sponsor < /b > : Sanofi Pasteur, a Sanofi Co...
Source: ClinicalTrials.gov - July 15, 2016 Category: Research Source Type: clinical trials
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older
< b > Conditions < /b > : Meningitis; Meningococcal Meningitis; Meningococcal Infections < br/ > < b > Interventions < /b > : Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine; Biological: Meningococcal Polysaccharide Vaccine, Groups A, C, Y, and W 135 Combined < br/ > < b > Sponsor < /b > : Sanofi Pasteur, a Sanofi Company < br/ > < b > Recruiting < /b > - verified July 2016 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 15, 2016 Category: Research Source Type: clinical trials
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older
Conditions: Meningitis; Meningococcal Meningitis; Meningococcal Infections Interventions: Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine; Biological: Meningococcal Polysaccharide Vaccine, Groups A, C, Y, and W 135 Combined Sponsor: Sanofi Pasteur, a Sanofi Company Active, not recruiting - verified July 2016 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 15, 2016 Category: Research Source Type: clinical trials
Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine
Conditions: Meningitis; Meningococcal Meningitis; Meningococcal Infections Interventions: Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine; Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine; Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine; Biological: Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine Sponsor: Sanofi Pasteur, a Sanofi Company Recruiting - verified July 2016 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 15, 2016 Category: Research Source Type: clinical trials
